Brodalumab

Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
April Clinical Considerations for NP's, PAsIn this month's Clinical Considerations, we look at handling the difficult patient, how to improve our diagnostic skills and the latest psoriasis drug approval.
Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Three drug trends impacting specialty pharmacyAMCP session, “Specialty Pharmaceutical in Development,” highlighted critical trends that healthcare executives should be watching
New psoriasis therapies must demonstrate valuePsoriasis affects a small percentage of the population but price increases for drug treatments have outpaced the Consumer Price Index.
Brodalumab demonstrates positive results in plaque psoriasis studyA phase 3 trial of brodalumab (AMG 827) for the treatment of patients with moderate-to-severe plaque psoriasis demonstrated positive results, meeting primary and secondary endpoints.